P = 0.169). CTGF was signifi cantly increased in the banding group (89.0[84.0] vs. 126[106.0]pg/mL, P = 0.012) but not in the debanding group compared with the sham group (89.0[84.0] vs. 127.0[88.0]pg/mL, P = 0.447).
Results: Administration of cilostazol signifi cantly increased the expression of hepatocyte growth factor (HGF), vascular endothelial growth factor, angiopoietin-1, and peroxisome proliferator-activated receptor (PPAR)-␥ in vasculature. The capillary density in ischemic leg was also signifi cantly increased in cilostazol treatment group as compared to control and aspirin treatment group. However, an increase in capillary density and the expression of growth factors was almost completely abolished by co-administration of HGF-neutralizing antibody, suggesting that cilostazol enhanced angiogenesis mainly through HGF. In vitro experiment revealed that cilostazol treatment increased HGF production in vascular smooth muscle cells via two major pathways, PPAR-␥ and cAMP pathways.
Conclusions:
Our data suggest that the favorable effects of cilostazol on ischemic leg might be through the angiogenesis through the induction of HGF via PPAR-␥ and cAMP pathways. Objective: to study the distribution of promoter polymorphisms of matrix metalloproteinases MMP2 (-1306C / T) and MMP9 (-1562C / T) and assess the condition of the aortic stiffness in patients with hypertension (H) in young and middleaged, including the metabolic syndrome (MS).
PS 13-11 MMP2 AND MMP9 PROMOTER POLYMORPHISMS AND ARTERIAL STIFFNESS IN THE YOUNG AND MIDDLE AGED PATIENTS WITH HYPERTENSION

Design and method:
We recruited 58 hypertensive participants (25-60 years old). The 35 (people) have MS. A control group included 20 healthy people. Arterial stiffness was measured by pulse wave velocity (PWV). For genotyping, DNA samples were obtained from peripheral blood leukocytes. Identifi cation of the mutations was performed by direct sequencing of PCR products. Association between these variables and PWV values was evaluated using risk ratio (RR).
Results:
The pathological allele MMP2 (-1306T) was occurred with equal frequency in the control group and the group with hypertension and MS, without statistically signifi cant differences (p > 0.1). The MMP9 (-1562T) pathological allele was more represented in the control group, but the difference observed had no statistical signifi cance (p > 0.1). When comparing the group with a truly high PWV, including those with hypertension and hypertension in conjunction with the MS, with the group with hypertension and normal PWV, we found a relationship between the presence of the MMP9 T allele and excessive arterial stiffness (OR = 1.9; p < 0.1).
Conclusions:
We found the closest relationship between arterial stiffness and the MMP9 (-1564T) allele, which was associated with a nearly threefold increase in the risk of occurrence of accelerated PWV among people with hypertension in young and middle-aged. Objective: To study the distribution of the Adiponectin receptor 1 (AdipoR1) in skeletal muscle of people with hypertension in young and middle age.
Design and method: 30 biopsies of skeletal muscle of patients with hypertension I -III degree at the age of 25 to 60 years were operated on for traumatic shoulder fractures. As a control, biopsies of skeletal muscle 10 volunteers were used, operated on for traumatic fractures without hypertension and other comorbidities. Expression of the receptor to adipokines-1 was determined by immunohistochemistry using a primary polyclonal rabbit antibody against AdipoR1 (Santa Sruze, sc-99183, USA, 1: 500). Secondary antibody and streptavidin were obtained from Thermo scientifi c. The images were processed using the program Adobe Photoshop 7.0 and Image J. The signifi cance of differences between groups (at p < 0,05) were evaluated using the Mann-Whitney factor.
Results: Precipitate density of the muscle fi bers in patients with hypertension was focal and took signifi cantly less space than in the control group (21,85 ± 12,34% against 63,76 ± 24,14%, p < 0.005). The color intensity in hypertension also was signifi cantly lower compared with the control group (93,97 ± 18,45 and 162,04 ± 19,76, p < 0.05). At the same time, unlike the control, in patients with hypertension, large area representation receptor adipokine secretion installed in the connective tissue (40,27 ± 25,21%, in the control group -4,89 ± 17,01%, p < 0.005). However, the precipitate density in the connective tissue in both groups was comparable to each other (114,97 ± 30,51 and 144,97 ± 10,51, p > 0.05).
Thus, the shoulder in biopsies of patients with hypertension observed misplacement of receptor AdipoR1 compared with the control, namely the reduction of the area and intensity of the secretion of the receptor in muscle tissue and an increase in its intensity with preservation of connective tissue. Objective: Manganese superoxide dismutase (MnSOD) is an important antioxidant enzyme affected in heart/muscle-specifi c MnSOD-defi cient mice (H/M-SOD2 −/− ), which develop progressive congestive heart failure and exhibit pathology typical of dilated cardiomyopathy.
Design and method:
In this study we investigated the benefi cial effects of epigallocatechin gallate (EGCG) on the cardiac remodeling and telomere biology in H/M-SOD2 −/− mice.
Methods: H/M-SOD2 −/− mice were divided into three groups: those receiving normal drinking water (KO), a low dose of EGCG (L: 10 mg/L) and a high dose of EGCG (H: 100 mg/L) beginning at eight weeks of age and lasting for eight weeks.
Results:
The mice in the KO group exhibited signifi cantly dilated cardiac remodeling with reduced contractility, which was prevented by the administration of EGCG. Although the mortality of KO mice was about 50% at 16 weeks of age, the mice that received EGCG had a high survival rate. The cardiac dilatation with reduced cardiac contraction in KO mice was prevented by EGCG treat-
